Literature DB >> 31632756

Evaluation and classification of pulmonary arterial hypertension.

Sandeep Sahay1.   

Abstract

In early 2019, the 6th World Symposium on Pulmonary Hypertension (WSPH) released an updated document highlighting the advances in the last five years. During the quinquennial event many experts worked together to suggest new changes in the disease diagnosis and management. Since inception of the WSPH in 1973, this is the first time when the hemodynamic definition of pulmonary hypertension (PH) has been updated. These proceedings have re-defined the different hemodynamic types of PH that occur with the left heart disease along with introduction to the genetic testing as part of pulmonary arterial hypertension (PAH) evaluation. Objective of this review is to highlight the evaluation and diagnosis of PAH based on the proceedings of the 6th WSPH. Accurate early diagnosis and subsequent management of PH is necessary, as despite of treatment advances, survival remains suboptimal. 2019 Journal of Thoracic Disease. All rights reserved.

Entities:  

Keywords:  6th World Symposium on Pulmonary Hypertension (6th WSPH); Pulmonary hypertension (PH); chronic thromboembolic pulmonary hypertension (CTEPH); pulmonary arterial hypertension (PAH); pulmonary veno-occlusive disease (PVOD)

Year:  2019        PMID: 31632756      PMCID: PMC6783722          DOI: 10.21037/jtd.2019.08.54

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  58 in total

Review 1.  Chronic thromboembolic pulmonary hypertension.

Authors:  P F Fedullo; W R Auger; K M Kerr; L J Rubin
Journal:  N Engl J Med       Date:  2001-11-15       Impact factor: 91.245

2.  An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.

Authors:  Raymond L Benza; Dave P Miller; Robyn J Barst; David B Badesch; Adaani E Frost; Michael D McGoon
Journal:  Chest       Date:  2012-08       Impact factor: 9.410

3.  Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

Authors:  Olivier Sitbon; Marc Humbert; Xavier Jaïs; Vincent Ioos; Abdul M Hamid; Steeve Provencher; Gilles Garcia; Florence Parent; Philippe Hervé; Gérald Simonneau
Journal:  Circulation       Date:  2005-06-06       Impact factor: 29.690

4.  Mild Elevation of Pulmonary Arterial Pressure as a Predictor of Mortality.

Authors:  Philipp Douschan; Gabor Kovacs; Alexander Avian; Vasile Foris; Fabian Gruber; Andrea Olschewski; Horst Olschewski
Journal:  Am J Respir Crit Care Med       Date:  2018-02-15       Impact factor: 21.405

5.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

Authors:  David B Badesch; Gary E Raskob; C Greg Elliott; Abby M Krichman; Harrison W Farber; Adaani E Frost; Robyn J Barst; Raymond L Benza; Theodore G Liou; Michelle Turner; Scott Giles; Kathy Feldkircher; Dave P Miller; Michael D McGoon
Journal:  Chest       Date:  2009-10-16       Impact factor: 9.410

6.  Exome Sequencing in Children With Pulmonary Arterial Hypertension Demonstrates Differences Compared With Adults.

Authors:  Na Zhu; Claudia Gonzaga-Jauregui; Carrie L Welch; Lijiang Ma; Hongjian Qi; Alejandra K King; Usha Krishnan; Erika B Rosenzweig; D Dunbar Ivy; Eric D Austin; Rizwan Hamid; William C Nichols; Michael W Pauciulo; Katie A Lutz; Ashley Sawle; Jeffrey G Reid; John D Overton; Aris Baras; Frederick Dewey; Yufeng Shen; Wendy K Chung
Journal:  Circ Genom Precis Med       Date:  2018-04

7.  Pulmonary function in primary pulmonary hypertension.

Authors:  Xing-Guo Sun; James E Hansen; Ronald J Oudiz; Karlman Wasserman
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

8.  Pulmonary arterial hypertension in patients treated by dasatinib.

Authors:  David Montani; Emmanuel Bergot; Sven Günther; Laurent Savale; Anne Bergeron; Arnaud Bourdin; Helene Bouvaist; Matthieu Canuet; Christophe Pison; Margareth Macro; Patrice Poubeau; Barbara Girerd; Delphine Natali; Christophe Guignabert; Frédéric Perros; Dermot S O'Callaghan; Xavier Jaïs; Pascale Tubert-Bitter; Gérard Zalcman; Olivier Sitbon; Gérald Simonneau; Marc Humbert
Journal:  Circulation       Date:  2012-03-26       Impact factor: 29.690

9.  Characterization and clinical significance of right ventricular mechanics in pulmonary hypertension evaluated with cardiovascular magnetic resonance feature tracking.

Authors:  Maria Eduarda Menezes de Siqueira; Eduardo Pozo; Veronica R Fernandes; Partho P Sengupta; Karen Modesto; Sushilkumar Satish Gupta; Cayetana Barbeito-Caamaño; Jagat Narula; Valentin Fuster; Adriano Caixeta; Javier Sanz
Journal:  J Cardiovasc Magn Reson       Date:  2016-06-16       Impact factor: 5.364

Review 10.  Genetics and genomics of pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Micheala A Aldred; Wendy K Chung; C Gregory Elliott; William C Nichols; Florent Soubrier; Richard C Trembath; James E Loyd
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

View more
  12 in total

Review 1.  Oxidative Stress and Antioxidative Therapy in Pulmonary Arterial Hypertension.

Authors:  Dan Xu; Ya-Hui Hu; Xue Gou; Feng-Yang Li; Xi-Yu-Chen Yang; Yun-Man Li; Feng Chen
Journal:  Molecules       Date:  2022-06-09       Impact factor: 4.927

Review 2.  Connexins may play a critical role in cigarette smoke-induced pulmonary hypertension.

Authors:  Xiaojiang Qin; Anqi Gao; Xiaomin Hou; Xinrong Xu; Liangjin Chen; Lin Sun; Yuxuan Hao; Yiwei Shi
Journal:  Arch Toxicol       Date:  2022-03-27       Impact factor: 6.168

3.  Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis.

Authors:  Miaofa Ying; Jin Song; Shenglong Gu; Rui Zhao; Mingxing Li
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

4.  Clinical and hemodynamic outcomes and mortality risk factors in patients undergoing pulmonary thromboendarterectomy.

Authors:  Cristhian F Ramirez-Ramos; Clara Saldarriaga-Giraldo; Manuela Yepes-Calderon; Gustavo Castilla-Agudelo; Mateo Aranzazu-Uribe; Santiago Saldarriaga-Betancur; Paulina Castro; Alejandro Londoño; Hector Ortega; Jorge Zapata-Sanchez; Eliana Cañas; Juan C Rendon-Isaza
Journal:  Arch Cardiol Mex       Date:  2022-07-01

5.  Resistin-like molecule β acts as a mitogenic factor in hypoxic pulmonary hypertension via the Ca2+-dependent PI3K/Akt/mTOR and PKC/MAPK signaling pathways.

Authors:  Heshen Tian; Lei Liu; Ying Wu; Ruiwen Wang; Yongliang Jiang; Ruicheng Hu; Liming Zhu; Linwei Li; Yanyan Fang; Chulan Yang; Lianzhi Ji; Guoyu Liu; Aiguo Dai
Journal:  Respir Res       Date:  2021-01-06

6.  Astragaloside IV blocks monocrotaline‑induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling.

Authors:  Haifeng Jin; Yu Jiao; Linna Guo; Yong Ma; Rongjie Zhao; Xuemei Li; Lei Shen; Zhongguang Zhou; Sang Chan Kim; Jicheng Liu
Journal:  Int J Mol Med       Date:  2020-12-08       Impact factor: 4.101

Review 7.  An Overview of miRNAs Involved in PASMC Phenotypic Switching in Pulmonary Hypertension.

Authors:  Weifang Zhang; Zeying Tao; Fei Xu; Qian Diao; Juan Li; Lu Zhou; Yaxin Miao; Shanshan Xie; Jinjin Wan; Ruilai Xu
Journal:  Biomed Res Int       Date:  2021-10-07       Impact factor: 3.411

Review 8.  Signal Transduction during Metabolic and Inflammatory Reprogramming in Pulmonary Vascular Remodeling.

Authors:  Marta T Gomes; Yang Bai; Simone R Potje; Lu Zhang; Angelia D Lockett; Roberto F Machado
Journal:  Int J Mol Sci       Date:  2022-02-22       Impact factor: 5.923

9.  Evaluation, Diagnosis, and Classification of Pulmonary Hypertension.

Authors:  Beshay Sarah; Guha Ashrith; Sahay Sandeep
Journal:  Methodist Debakey Cardiovasc J       Date:  2021-07-01

10.  Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up.

Authors:  Verônica Silva Vilela; Marcio Macri Dias; Ângelo Antunes Salgado; Bruno Rangel Antunes da Silva; Agnaldo José Lopes; Elizabeth Jauhar Cardoso Bessa; Leonardo Palermo Bruno; Cláudia Henrique da Costa; Roger Abramino Levy; Rogério Rufino
Journal:  BMC Pulm Med       Date:  2021-07-29       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.